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Abstract
C-Met is a receptor tyrosine kinase with multiple functions throughout embryonic development, organogenesis and
wound healing and is expressed in various epithelia. The ligand of c-Met is Hepatocyte Growth Factor (HGF) which
is secreted among others by mesenchymal stroma/stem (MSC) cells.
Physiological c-Met functions are centred around processes that underly cellular motility and invasive growth.
Aberrant c-Met expression and activity is observed in numerous cancers and makes major contributions to cell
malignancy. Importantly, HGF/c-Met signaling is crucial in the context of communication between cancer cells and
the the tumor stroma.
Here, we review recent findings on roles of dysregulated c-Met in urogenital tumors such as cancers of the urinary
bladder, prostate, and ovary. We put emphasis on novel aspects of cancer-associated c-Met expression regulation
on both, HGF-dependent and HGF-independent non-canonical mechanisms. Moreover, this review focusses on c-
Met-triggered signalling with potential relevance for urogenital oncogenesis, and on strategies to specifically inhibit
c-Met activity.
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Background
c-Met (mesenchymal epithelial transition factor) is a
multifunctional transmembrane tyrosine kinase and acts
as a receptor for hepatocyte growth factor/Scatter factor
(HGF/SF) [1]. It is expressed in various epithelial tissues
(liver, pancreas, prostate, kidney, muscle, bone-marrow)
during embryogenesis [2] and is also found on the cell
surface of numerous tumorous cell populations. Shortly
after its discovery, multiple oncogenetic properties of
c-Met were described, including the stimulation of
cell dissociation, migration, motility, and invasion of
extracellular matrix [3–6]. Formation of mature c-Met
is achieved by proteolytic cleavage of a precursor in a
post-Golgi compartment, resulting in a small alpha
and large beta polypeptide which then associate into
a heterodimer. A disulfide bridge connects the small
alpha unit and the extracellular segment of the membrane
spanning beta subunit [7]. The extracellular part of the
beta subunit is composed of an N-terminal sematophorin
(sema) domain (essential for receptor activation) followed
by a cysteine-rich portion (plexin sematophorin domain)
and four IPT (immunoglobulin like plexins transcription
factor) domains. A transmembrane helix connects the
extracellular domain of c-Met to its intracellular section
which can be divided into a juxtamembrane domain, a
tyrosine kinase domain and the C-terminal region [2]
(Figs. 1 and 2).
Structure and function of c-Met
C-Met becomes activated through homo-dimerisation
upon binding of its ligand HGF [8–12]. As a result of
ligand-induced dimerization, the intracellular tyrosine
kinase domains of the two receptor beta-subunits trans-
phosphorylate each other at residues Tyr1234 and Tyr1235
within the catalytic loops [13]. This event fully unleashes
the tyrosine kinases which subsequently catalyze further
phosphorylation of the receptor chain at Tyr1003 in the
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juxtamembrane domain and Tyr1349/Tyr1356 within the
C-terminal region (Fig. 1). These modifications relay fur-
ther signals by generating specific contact interfaces
(pTyr-containing motifs) with a variety of different src
homology domain 2 (SH2) containing adaptor molecules
to eventually regulate induction of cell motility, prolifer-
ation, invasiveness, and tubular morphogenesis [14–22].
C-Met receptor downstream signaling is mediated by
recruitment of distinct adaptor and effector proteins
such as src-homology-2- (SH2-), src-homology-3- (SH3-)
domain-containing proteins and phospho-tyrosine-
binding proteins (PTB) (Fig. 1). These adaptor proteins
without enzymatic activity include Grb2 (growth factor
receptor-bound protein 2), CRK ((CT10 (chicken tumor
virus number 10) regulator of kinase)), and GAB1 (GRB2-
associated binding protein 1). C-Met-binding proteins
with enzymatic activity include Src kinases, PI3K (phos-
phatidylinositol 3-kinase), PLC-γ1 (phospholipase C-γ1),
SHIP-2 (SH2 domain-containing 5’ inositol phosphatase),
STAT-3 (signal transducer and activator of transcription),
SOS (Ras guanine nucleotide exchange factor son-of-
seven), PTPs (protein tyrosine phosphatases), e.g. SHP2
(SH2 domain-containing phosphatase-2) [14, 16–23].
HGF-stimulated c-Met activation can also phosphorylate
downstream targets such as p44/42 MAP kinase (ERK) to
mediate enhanced proliferation and cell cycle progression
[2, 24, 25] (Fig. 1). In addition, Met can be activated even
in the absence of HGF. In this context, Fan et al. described
a novel HGF-indepedent mechanism in which non-
receptor tyrosine kinase FER is involved. The upregulation
of FER in ovarian cancers could trigger a signaling cascade
downstream of c-Met in a HGF independent manner.
Mechanistically, FER was shown to phosphorylate the
tyrosine residue of the C-terminal SH2 domain docking
site of c-Met, thus maintaining recruitment of signaling
molecules such as GAB1 and Grb2 to the receptor.
Most importantly, FER-mediated downstream signal-
ling by c-Met could not be inhibited by a c-Met in-
hibitor alone [26].
Intra- and intercellular signaling triggered by c-Met in
urogenital cancers
Activated c-Met in normal cells – predominantly in
stromal cells including MSC - plays a major role in
organogenesis and wound healing whereas in tumor
cells, HGF-activated c-Met contributes to invasive and
metastatic behavior [12, 27]. Various urogenital cancers
like muscular-invasive urinary bladder cancer, prostate
cancer and ovarian cancer express c-Met [28–30]. c-Met
can be detected in about 70% of the different types of
ovarian cancers such as low and high grade serous,
endometrioid, clear cell and mucinous carcinomas, in
Fig. 1 HGF/SF-mediated activation of c-Met and relayed downstream signalling. The c-Met receptor can be structured into distinct domains, including
sema, cysteine-rich, immunoglobulin, trans-membrane, juxta-membrane, tyrosine kinase, and C-terminal region. Pharmacological intervention with
activated c-Met signalling includes: (i) competitive interference with HGF/c-Met interaction, (ii) inhibition of the tyrosine kinase activity of c-Met with
the use of tyrosine kinase inhibitors (TKI), or (iii) blocking of activated c-Met downstream signaling mediators. Accordingly, cell fate and development
such as survival, transformation, cell motility, and proliferative capacity can be affected. This figure was adapted from Organ and Tsao, 2011 [2]
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about 30% of the tumors c-Met is expressed to a notice-
ably high degree [31–33]. C-Met over-expression is
observed particularly in hyperactive tumors which also
show elevated angiogenesis and neo-vascularization due
to activity of vascular endothelial growth factor
receptor-2 (VEGF-R2). These tumor properties correlate
with poor prognosis [34–36].
In prostate cancer, it was shown that androgen
deprivation is connected with a more aggressive phenotype
and leads to an increased c-Met expression. In parallel, the
androgen receptor, which is known as a negative regulator
of c-Met, is downregulated [37–39]. Hence, c-Met signal-
ing obviously has an important role in maintaining survival
as well as proliferation in androgen receptor-independent
prostate cancer cells [40]. In this context, evidence has
been obtained for an association of c-Met activation with
decreased expression of genes related to DNA repair. It
was, thus, suggested that c-Met may contribute to the
accumulation of DNA damage and mutations and conse-
quently favor progression of castration-resistant prostate
cancer [40].
A recent report shows that c-Met upregulation in cas-
tration-resistant prostate cancer tissue is associated with a
different distribution pattern compared to biopsies from
naïve prostate cancer tissue. Interestingly, a c-Met frag-
ment lacking the c-terminal part of full-length membran-
ous c-Met was found to accumulate in the nuclei of
Fig. 2 Pathways of c-Met signaling. a Overview of HGF/c-Met signaling
via the canonical and non-canonical pathway. Canonical or “classical”
HGF/Met signaling involves ligand-dependent and independent receptor
activation which leads to the induction of downstream signaling
cascades (left). Non-canonical HGF/c-Met signaling is independent of
receptor activation. Generation of c-Met receptor fragments takes place
under various cellular conditions such as apoptotic and necrotic stimuli
as well as in the context of specific physiological circumstances. HGF is
also able to exert signals independently of c-Met, e.g. upon interactions
triggered by its heparin-binding domain. b Generation of c-Met
fragments via shedding and cleavage by γ-secretase: Sheddases or
metalloproteinases cleave full-length c-Met within its extracellular
domain, resulting in different in a soluble extracellular N-terminal
fragment (Met-NTF) and a membrane-associated C-terminal fragment
(Met-CTF). Met-CTF can be further processed by the γ-secretase complex
by presenilin-dependent intramembrane proteolysis (PS-RIP) into an
intracellular domain (Met-ICD) which is routed to proteasomal
degradation. Full-length membranous c-Met can also be internalized
and cleaved by sheddases giving rise to Met-NTF and Met-CTF. These
intracellularly generated c-Met fragments undergo lysosomal instead
of proteasomal degradation. c Origin of c-Met fragments through
intracellular cleavage by caspases and calpains: In response to apoptotic
stimuli, c-Met is cleaved at two distinct sites in the intracellular domain
by activated caspase-3, resulting in membrane-anchored p100 Met, a
40 kDa cytosolic p40 Met fragment and a small peptide (M10). Under
necrotic conditions, c-Met is cleaved by metalloproteinases and further
processed by calcium-independent proteases (calpains) instead of
γ-secretase. The resulting product p40 Metcalpain differs from p40
Metcaspase by a few amino acid residues and is not able to
promote apoptosis
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tumor cells preferentially in castration-resistant prostate
cancer [41]. These results support the notion of a role for
full-length and processed c-Met in the progression of
androgen-independent prostate cancer.
Elevated c-Met expression in tumor cells also leads to
enhanced c-Met activity within the tumor tissue, since
profound HGF expression within the tumor stroma acti-
vates c-Met on cancer cells in a paracrine manner. HGF
expression was shown to be clearly increased in urogeni-
tal cancers such as urinary bladder, prostate and ovarian
cancer [42–45]. In prostate and bladder cancer, c-Met-
related feedback activation crosstalk between carcinoma
cells and tumor-associated fibroblasts was characterized:
HGF secretion becomes upregulated in stromal fibro-
blasts co-cultured with tumor cells, which in turn
enhances migratory and invasive properties of cancer
cells [44, 46–51]. However, in normal ovary HGF is
mainly detected in the ovarian surface epithelium on the
outer surface of the ovary and to a lesser extend in ovar-
ian stromal cells directly adjacent to the ovarian surface
epithelium [45]. Moreover, an elevated HGF expression
is detectable in epithelial cell components of ovarian
tumors and in MSC suggesting an autocrine and/or
paracrine stimulation of ovarian tumor growth including
tumor cell protection [45, 52–54]. In other cancer
entities such as gastric and colon cancer, HGF/c-Met
signaling was shown to be operative in fibroblasts within
the tumor microenvironment, thereby contributing to
tumor progression [55, 56]. Moreover, immunohistochem-
ical analysis showed c-Met expression on myofibroblasts
mainly in the invasive area of lung adenocarcinoma [57].
c-Met expression on myofibroblasts in patients with
small-sized lung adenocarcinoma was correlated with
shortened patient survival [57]. It will be important to
address in how far HGF-mediated fibroblast activation
does also play a role in urogenital cancers.
Non-canonical signaling by c-Met
It is now well established that receptor tyrosine kinases
can also act via signaling pathways other than the Ras/Raf
cascade. “Canonical signaling” is currently used as a term
for the signaling route extending from ligand binding to
the cell surface exodomains of receptors resulting in
dimerization/oligomerisation and receptor trans-/ auto-
phosphorylation with subsequent intracellular signal
release. Recently, “non-canonical signaling” has emerged
as a concept to describe the specific generation of defined
intracellular tyrosine kinase receptor fragments which
have different functions [58]. The formation of these
fragments is achieved by the activity of different proteases
whose functions can be dependent or independent of
receptor stimulation by ligand (Fig. 2).
Four cleavage products of c-Met with potential functions
in signaling have as yet been described. The extracellular
N-terminal fragment (Met-NTF) can be eliminated from
the full-length receptor by metalloproteinases such as
ADAM-10 and ADAM-17. Subsequent processing of the
membrane-proximal C-terminal fragment (Met-CTF)
by presenilin-dependent, regulated, intramembrane
proteolysis (PS-RIP) results in an intracellular c-Met
fragment (Met-ICD) which becomes subject to protea-
somal degradation [59–62]. It is controversal as to
whether the extracellular soluble domain of c-Met
(NTF) exerts the physiological function of sequester-
ing and, thus, antagonizing HGF/SF and is also a
potent antagonist to the antagonist [63–65]. However, in
mouse xenograft experiments with injected UOK261
bladder carcinoma cells, which show a high proteolytic
cleavage rate of the full-length receptor, a linear relation-
ship between soluble c-Met in the plasma or urine and
total tumor volume was shown [63, 64]. Moreover, the
level of soluble c-Met in urine from bladder cancer
patients was shown to be a disease marker and to even
allow for distinction between tumor stages as muscle no-
invasive and invasive cancers [66]. These findings suggest
that cleavage of c-Met plays a role in urinary bladder
cancer progression.
By shedding the Met-NTF, the resulting fragments
Met-NTF and-CTF can also be lysosomally degraded.
Ancot et al. published a model describing the fate and
subcellular location of the receptor-derived breakdown
products post processing of the full-length cell surface
receptor by PS-RIP and its proteasomal degradation
upon removal of Met-NTF. However, if c-Met is
membrane-bound and internalized, it can also undergo
intracellular proteolytic cleavage. This process gives rise
to Met-NTF and Met-CTF, which can subsequently be
degraded lysosomally. Thus, fragment Met-CTF escapes
processing by PS-RIP when the cleavage takes place
intracellularly [67]. Both shedding-induced degradation
pathways are independent of receptor activation and
may serve the function of preventing overexpression and
"over-activation" of c-Met [60, 61, 67].
Experimental overexpression of a segment comprising
only the intracellular segment of c-Met devoid of the
extracellular domain in NIH3 Ts fibroblasts showed an
elevated oncogenic potential with enhanced proliferation
and invasiveness compared to control fibroblasts [68].
Interestingly, constitutively active c-Met fragments were
detected in cell nuclei of an aggressive breast carcinoma
cell line. They showed trans-activating activity in an
experimental Gal4-based transactivation assay and ap-
pear to have a function in connection with spontaneous
migratory behaviour of this cell line [69]. However, the
absence of tumor suppressor Wwox plays a role here.
Wwox is believed to possess regulatory functions in both
controlling the stability of full-length c-Met and in the
inhibition of the transactivation function of nuclear
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Met-CTF [69]. As already mentioned above, the nuclear
Met-ICD level is higher in castration-resistant than in
naïve prostate cancer. Withdrawal of androgens upregu-
lates nuclear Met-ICD which in turn activates transcrip-
tion factor SOX9 and the β-catenin/ androgen receptor
signaling pathway. In combination, this promotes cell
transformation and three-dimensional tumor growth in
castration-resistant prostate cancer [41]. These results
suggest that proteolytically generated c-Met fragments
that are not lysosomally or proteasomally degraded and
thus, accumulate in the cell which can contribute to
tumor progression. However, as yet little is known about
the precise physiological or pathological mode of action
and function of these fragments.
c-Met cleavage products are functional in the control
of cell death and survival [70]. The receptor can be
cleaved intracellularly at two distinct sites in response to
stress stimuli. The resulting 40 kD cytosolic p40Met
fragment, in contrast to the ligand-activated full-length
receptor, acts pro-apoptotically via the mitochondrial
permeabilization process of the intrinsic apoptotic
pathway. Caspase-3 was identified as the responsible
protease for the cleavage of c-Met [71–73].
Cleavage of c-Met yields the intracellular p40Met frag-
ment, a membrane-bound p100Met fragment and, in
addition, a peptide ten amino acid residues in length
designated M10 and corresponding to C-terminal end of
the receptor protein [74, 75]. The p100Met fragment
encompassing the entire extracellular domain, is still
membrane-bound and can act as a scavenger of HGF/SF,
thereby serving as an inhibitor of the HGF/c-MET signal
cascade [74]. M10 can block TGF-β-induced SMAD2
phosphorylation by interaction with SMAD2 and, thus,
exerts antifibrotic effects [75].
The ratio of full-length c-Met and caspase-3 appears to
have an influence on the extent of apoptosis in hepato-
cytes: High abundance of c-Met can suppress caspase-3
activity and, thus, suppress apoptosis. Under conditions of
a strong apoptotic stimulus, however, this inhibitory effect
of c-Met on caspase-3 is overcome and cell death is no
longer blocked [76].
Remarkably, caspase-3 is also active in non-apoptotic
melanoma and glioblastoma cells as well as in invasive
bladder cancer promoting tumor progression [77–79].
Mukai et al. published that cancer cells are able to react
on apoptotic stimuli with a higher invasiveness through
caspase activation [80]. Until now there is no evidence
for a role of caspase-3 mediated cleavage of c-Met in this
context. Moreover, c-Met also becomes cleaved in necro-
sis [81] whereby c-Met can be shed by metalloproteases as
discussed above and instead of further processing by the
γ-secretase complex, it becomes degraded by calcium-
dependent proteases (calpains). This process gives rise to
a 40 kDa Met fragment designated p40Met calpain which
differs from the previously described p40Met caspase frag-
ment in a few amino acids and its inability to promote
apoptosis [81]. Moreover, the mutation R970C found in
lung cancer within the juxtamembrane domain of c-Met
promotes the calpain-dependent formation of a novel
45 kDa fragment p45Met, particularly in confluent cells
[82]. Overexpression of p45Met in epithelial cells en-
hances HGF-mediated cell scattering and invasion without
induction of tyrosine kinase activity of p45Met. This indi-
cates an alternative mechanism besides activation of cell
scattering by full length receptor [82]. In addition, ectopic
expression of R970C variant of Met in the suspension cell
line Ba/F3 did not show any transforming capacity,
supporting that HGF treatment, proteolytic cleavage and
cell confluence are probably necessary for cancer-related
effects of this variant [83].
Analysis of Met-overexpressing tumor samples from
patients with non-small cell lung cancer demonstrated
the existence of all Met fragments suggesting a variety of
cellular conditions within lung tumors [81]. However,
little is known about the role of the different c-MET
fragments in tumor progression so far.
Interestingly, not only c-Met can contribute to tumor
progression in a ligand-independent manner. Tate et al.
indicated a role for c-Met ligand HGF in prostate cancer
in the absence of its receptor [84]. HGF induces cell
adhesion and migration in a c-Met-negative prostate
cancer cell line on the basis of a low-affinity interaction
between its heparin-binding domain and nucleolin.
Nucleolin is a nuclear protein which is known to localize
also to the surface of cells. In this setting, it may link HGF
and integrin function [84]. Low or high concentrations of
HGF have been observed to exert distinct functions also
on non-tumorigenic cells, leading to the postulation that
HGF can elicit cellular effects in a c-Met-independent
manner in parallel with or alternatively to “classical”
c-Met/HGF signaling [85, 86].
Experimental and pharmacological interference with c-Met
activity in urogenital cancer cells
The identification of prominent c-Met expression in
certain urogenital tumors suggested that the HGF/SF –
c-Met axis may serve as an attractive target to be
included into chemotherapeutic regimens. Different
approaches have been taken towards molecularly target-
ing c-Met and HGF such as (i) competitive interference
with HGF/c-Met interaction, (ii) inhibition of the tyro-
sine kinase activity of c-Met, or (iii) blocking of activated
c-Met downstream signaling mediators (Fig. 1). Accord-
ingly, several preclinical studies indicated that inhibition
of c-Met represents a promising therapeutic strategy
paralleled by findings that c-Met overexpression has
prognostic value in urogenital cancers, particularly in
ovarian cancer.
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Using an ovarian cancer mouse model, the orally avail-
able c-Met inhibitor PF-2341066 was successfully applied
to reduce cell proliferation, adhesion and invasion as well
as to induce apoptosis [87]. This small-molecule inhibitor
shows specificity against c-Met and anaplastic lymphoma
kinase (ALK) and reduced mouse tumor size paralleled by
increased animal survival [88].
Another c-Met inhibitor, Crizotinib (PF-02341066),
represents a designed tyrosine kinase inhibitor based on
the core structure of the c-Met-inhibitor PHA 665752 in
which some functional groups of the originating mol-
ecule (PHA 665752) were altered. As a result Crizotinib
has stronger affinity for the ATP-binding pocket of the
kinase domain within the c-Met receptor. Consequently,
binding of ATP to the c-Met kinase domain and subse-
quent tyrosine phosphorylation of the receptor and
signal mediators are blocked [89, 90]. Moreover, Crizo-
tinib displays further inhibitory potential for the tyrosine
kinase receptor ALK and ROS1 (ROS proto-oncogene 1,
receptor tyrosine kinase) [91]. Crizotinib has, hence, been
approved for the treatment of ALK-positive non-small cell
lung carcinoma in the United States since August 2011.
Studies employing a combination of Crizitonib together
with PF-05212384 or gedatolisib were performed to add-
itionally inhibit the phosphatidyl inositol-3 kinase (PI3K)/
Akt/mammalian target of rapamycin (mTOR) signaling
pathway in the tumor cells. Results demonstrated superior
anti-tumor effects of this combination compared to the
individual agents. However, this combined treatment was
also associated with the development of a gedatolisib-
resistant subline, indicating increased expression of the
multi-drug-resistant-1 gene [92].
The orally administrable tyrosine kinase inhibitor
Foretinib (XL880, GSK1363089) exhibits a certain speci-
ficity and high affinity binding for both c-Met (IC50: 0.4
nM) and vascular epithelial growth factor receptor-2
(VEGF-R2/KDR) (IC50: 0.9 nM) [93]. This drug can also
bind to a variety of other growth factor receptors,
however, with significantly reduced binding affinities:
PDGFRα (IC50: 3,6 nM), PDGFRβ (IC50: 9.6 nM), RON
(IC50: 3 nM), c-KIT (IC50: 6,7 nM), FLT-3 (IC50: 3,6 nM)
und TIE-2 (IC50: 1,1 nM) and low affinities to FGFR1
(IC50: 660 nM), und EGFR (IC50: 2,9 μM) [93–95]. An
association of Foretinib with receptor tyrosine ki-
nases is accompanied by a conformational change
within the kinase structure and deprivation of en-
zymatic activity. Notably, Foretinib binding to its
target tyrosine kinases receptors remains stable for at
least 24 h [95].
Foretinib has also been demonstrated to block MAP
kinase signaling and cell cycle progression during in
vitro studies, substantiating this drug as a multi-target
tyrosine kinase inhibitor [96]. Promising in vivo studies
with significant Foretinib-mediated reduction of tumor
size were performed in NSCLC [91], in lung metastases
[93], and in Hedgehog medulloblastoma [97].
Potential effects of Foretinib as a multi-target tyrosine
kinase inhibitor besides its specificity for c-Met are also
focused on inhibition of VEGF-R2 signaling as an im-
portant pathway during angiogenesis and subsequent
neo-vascularization. Here, Foretinib exhibits properties
which primarily target the tumor microenvironment,
thereby displaying dual anti-tumorigenic strategies.
Promising effects of Foretinib in targeting VEGF-R2
signaling were achieved by an approximately 10-fold
reduction in tumor size of tumors of the rare and ag-
gressive small cell carcinoma of the ovary, hypercalcemic
type (SCCOHT), following tumor initiation by the two
model cell lines SCCOHT-1 and BIN-67, respectively.
MSC within the tumor microenvironment were shown to
contribute to this outcome [52, 53, 67, 98, 99]. Supportive
evidence of Foretinib’s anti-tumor activity through inhib-
ition of c-Met- and VEGFR-2-mediated signal transduc-
tion was also demonstrated in further tumor models e.g.
hepatocellular carcinoma [100], kidney cell carcinoma
[101] and gastric carcinoma [102].
The tumor microenvironment plays an pivotal role for
therapeutic approaches [103–105]. The importance
simultaneously targeting tumor cells and the tumor
microenvironment of urogenital cancers by anti-cancer
drugs in is also underscored by results with DCC-2701
as a c-Met/TIE-2/VEGF-R inhibitor [106]. In the course
of stroma–cancer cell interactions, human ovarian fibro-
blasts and MSC produced and secreted HGF, leading to
elevated growth and migration of ovarian cancer cells
coinciding with c-Met phosphorylation at Tyr1349.
Tumor treatment with DCC-2701 was able to efficiently
reduce the tumor burden in vivo by inhibition of c-Met
phosphorylation and c-Met-mediated signaling, for cell
growth and migration [106].
Conclusions
In summary, the abundance of c-Met expression and
intracellular signaling in urogenital cancers may provide
a selective molecular target for tumor therapeutic inter-
ventions. Moreover, multi-target c-Met tyrosine kinase
inhibitors with the property to simultaneously affect
cancer cells and the tumor microenvironment represent
efficient and focused drugs to target urogenital cancers.
In this context, it is important to note that cancer
growth and metastasis of c-Met-positive urogenital
cancers involves further stimuli besides HGF-binding
and subsequent c-Met signaling since no anti-tumor
effect was detectable in an ovarian cancer clinical trial
after using a humanized IgG2 antibody directed against
HGF (AMG-102), even though AMG-102 prevents HGF
binding to c-Met and subsequent c-Met activation [107].
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It is likely that the above-mentioned and not entirely
understood non-canonical c-Met signaling mechanisms
as well as c-Met-independent HGF activity are involved
in this phenomenon.
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